Democrats Confront Divisions Over Health Care in Debate

nytimes | June 28, 2019

It was a command as much as a question, intended to put an end to months of equivocating and obfuscating on the issue: Which of the Democratic presidential candidates on the debate stage supported abolishing private health insurance in favor of a single government-run plan? Show of hands, please.Just four arms went up over the two nights Senator Elizabeth Warren of Massachusetts and Mayor Bill de Blasio of New York on Wednesday, and Senators Bernie Sanders of Vermont and Kamala Harris of California on Thursday even though three candidates who kept their hands at their sides have signed onto bills in Congress that would do exactly that.And after the debate, Ms. Harris said that she had misunderstood the question, suggesting she had not meant to raise her hand either.

Spotlight

Healthcare executives expect that, within the next three years, their industry will need to focus as much on training machines as they do on training people, according to one finding from a new report by Accenture. The Accenture 2015 Healthcare IT Vision is based on a survey of doctors, consumers and healthcare executives and highlights emerging technology trends that will affect the health industry in the next three to five years. 84% of health executives surveyed agree or strongly agree that healthcare industry will need to focus as much on training machines – such as using algorithms, intelligent software and machine learning – as they do on training people in the next three years.


Other News
FUTURE OF HEALTHCARE

TRC Healthcare Expands Portfolio with the Acquisition of QURE Healthcare

TRC Healthcare | March 16, 2022

TRC Healthcare a trusted leader in continuing education, has acquired QURE Healthcare, a recognized innovator in clinical measurement and quality improvement. QURE's provider-focused solutions lead to better patient outcomes and lower costs for healthcare systems and coverage and reimbursement for life-science clients. TRC's acquisition paves the way for QURE to scale its innovative Clinical Performance and Value (CPV®) patient simulation software solutions. "Through the acquisition, TRC Healthcare intends to augment its already robust suite of products by focusing on improving patient outcomes with evidence-based training, education and continuing education/continuing medical education for physicians and other providers" TRC Healthcare's CEO,Wes Crews, announced. "QURE is excited to join a company that is so aligned with our mission to raise the quality of healthcare, standardize practice and lower costs by changing clinician behavior. Measuring and reducing care variation using CPV®vignettes is QURE's core business. We have demonstrated in the peer-review literature that we can do this from the ambulatory to the intensive care setting and for diseases ranging from angina to zoonoses, all with the goal to eliminate unwarranted variation, raise quality for patients and lower costs for payers." Dr.John Peabody, the founder and president of QURE TRC Healthcare regards QURE as another key addition to its recent acquisition of NetCE, an industry leading continuing education platform that educates nurses, physicians, and mental health professionals. Together, QURE and NetCE fortify the evidence-based healthcare solutions TRC offers, "The addition of QURE increases our link between strong education and better patient outcomes," remarkedWes Crews. Dr. Peabody will continue to serve as QURE's President and will take on the additional role of Chief Medical Officer at TRC Healthcare. Dr. Peabody is a renowned international health care figure in clinical care quality and a professor at theUniversity of California, San FranciscoandLos Angeles. In 2012, John started QURE Healthcare. The QURE platform – CPV® vignettes – has grown and become a widely adopted standard for measuring clinical practice. QURE CPVs are used by organizations looking to engage their providers in clinical variation reduction efforts, including large health care systems, independent practice associations, public and private payers, governments, non-governmental associations, and intergovernmental organizations. Dr. Peabody has contributed more than 200 articles, books, and abstracts to the peer-review literature, served on blue ribbon committees, testified before congress and advised heads of state on a wide variety of subjects notably quality improvement and the economic benefits of standardizing practice in healthcare systems. "QURE is an extraordinary company, with a validated product and team and an incredibly passionate community of users," saidWes Crews. "Together we can transform the way we engage providers and change patient care." About TRC Healthcare TRC Healthcare (TRC) is a premier source of lifelong learning solutions for healthcare professionals. TRC is most recognized for their education and CE offerings within the highly-regarded Pharmacist's Letter, Prescriber's Letter, and Pharmacy Technician's Letter. TRC also offers Pharmacy Technicians University, the leading online training program for pharmacy technicians. The Natural Medicines database makes it easy for subscribers to find unbiased, evidenced-based research about alternative drug therapies. Through the acquisition of CriticalPoint, NetCE and Bula TRC Healthcare has been expanding its offerings. CriticalPoint increases patient safety through a variety of educational compounding offerings concentrating on USP 797, 800, and 795. NetCE is an industry-leading, continuing- education platform supporting multiple professions including nurses, physicians, and mental health. And Bula provides legal and regulatory advice to retail pharmacies. These additions give TRC Healthcare the industry's largest catalog of continuing education and advisory services, with thousands of courses trusted by healthcare professionals to provide accredited training that meets continuing education and licensing requirements. About QURE QURE Healthcare is a provider engagement company committed to improving the quality of clinical care. using its proprietary technology, CPV®(Clinical Performance and Value) vignettes. CPV®vignettes

Read More

HEALTH TECHNOLOGY

Texas Children's Hospital And Baylor College of Medicine COVID-19 Vaccine Technology Secures Emergency Use Authorization In India

Texas Children Hospital | December 29, 2021

Texas Children's Hospital and Baylor College of Medicine announced today that CORBEVAX™, a protein sub-unit COVID-19 Vaccine, whose technology was created and engineered at its Center for Vaccine Development (CVD), has received Emergency Use Authorization (EUA) approval from the Drugs Controller General ofIndia(DCGI)to launch inIndiawith other underserved countries to follow. Dubbed "The World's COVID-19 Vaccine", it uses a traditional recombinant protein-based technology that will enable its production at large scales making it widely accessible to inoculate the global population. The initial construct and production process of the vaccine antigen was developed at Texas Children's Hospital CVD, led by co-directors Drs. Maria Elena Bottazzi and Peter Hotez and in-licensed from BCM Ventures, Baylor College of Medicine's integrated commercialization team, to Hyderabad-based vaccine and pharmaceutical company Biological E. Limited (BE). CORBEVAX™ after completing two Phase III clinical trials involving more than 3000 subjects was found to be safe, well tolerated and immunogenic: CORBEVAX™ demonstrated superior immune response in comparison with COVISHIELD™ vaccine when assessed for Neutralizing Antibody (nAb) Geometric Mean Titers (GMT) against the Ancestral-Wuhan strain and the globally dominant Delta variant. CORBEVAX™ vaccination also generated significant Th1 skewed cellular immune response. CORBEVAX™ nAb GMT against Ancestral-Wuhan strain is indicative of vaccine effectiveness of >90% for prevention of symptomatic infections based on the Correlates of Protection assessment performed during Moderna and Astra-Zeneca vaccine Phase III studies. CORBEVAX™ nAb GMT against the Delta strain indicates a vaccine effectiveness of >80 percent for the prevention of symptomatic infections based on published studies. While none of the subjects who took CORBEVAX™ or COVISHIELD™ had serious adverse events, CORBEVAX™ had 50 percent fewer adverse events than COVISHIELD™. In the continuous monitoring of phase II studies, CORBEVAX™ showed high persistence of immune response as indicated by <30% drop in nAb GMT till 6 months second dose as compared to >80% drop observed with majority of the vaccines. "Protein-based vaccines have been widely used to prevent many other diseases, have proven safety records, and use economies of scale to achieve low-cost scalability across the world," said Dr. Maria Elena Bottazzi, Professor and Associate Dean of the National School of Tropical Medicine at Baylor and Co-Director of the Texas Children's Hospital Center for Vaccine Development. "Our decade-long studies advancing coronavirus vaccine prototypes has led to the creation of this vaccine, which will fill the access gap created by the more expensive, newer vaccine technologies and that today are still not able to be quickly scaled for global production." The need for safe, streamlined, low-cost vaccines for middle- to low-income countries is central to the world's fight against the COVID-19 pandemic. Without widespread vaccination of populations in the Global South, additional virus variants will arise, hindering the progress achieved by currently available vaccines in the United States and other Western countries. "This announcement is an important first step in vaccinating the world and halting the pandemic. Our vaccine technology offers a path to address an unfolding humanitarian crisis, namely the vulnerability the low- and middle-income countries face against the delta variant," said Dr. Peter Hotez, Professor and Dean of the National School of Tropical Medicine at Baylor and Co-Director of the Texas Children's Hospital Center for Vaccine Development. "Widespread and global vaccination with our Texas Children's-Baylor-BE vaccine would also forestall the emergence of new variants. We have previously missed that opportunity for the alpha and delta variant. Now is our chance to prevent a new global wave from what might follow." "Over the years, we have worked to make quality vaccines and pharmaceutical products accessible to families around the world. With this as our backdrop, we resolved to develop an affordable and effective COVID-19 vaccine. It has now become a reality. We deeply appreciate Texas Children's Hospital Center for Vaccine Development, Baylor, CEPI, the Bill and Melinda Gates Foundation, and the government of India for their continuous support and cooperation during this journey. The combined efforts & unceasing support demonstrate that we can collectively overcome any challenge". Mahima Datla, Managing Director, Biological E. Limited ABOUT TEXAS CHILDREN'S HOSPITAL Texas Children's Hospital, a not-for-profit health care organization, is committed to creating a healthier future for children and women throughout the global community by leading in patient care, education and research. Consistently ranked as the best children's hospital in Texas, and among the top in the nation, Texas Children's has garnered widespread recognition for its expertise and breakthroughs in pediatric and women's health. The hospital includes the Jan and Dan Duncan Neurological Research Institute; the Feigin Tower for pediatric research; Texas Children's Pavilion for Women, a comprehensive obstetrics/gynecology facility focusing on high-risk births; Texas Children's Hospital West Campus, a community hospital in suburban West Houston; and Texas Children's Hospital The Woodlands, the first hospital devoted to children's care for communities north of Houston. The organization also created Texas Children's HealthPlan, the nation's first HMO for children; has the largest pediatric primary care network in the country, Texas Children's Pediatrics; Texas Children's Urgent Care clinics that specialize in after-hours care tailored specifically for children; and a global health program that's channeling care to children and women all over the world. Texas Children's Global Health program leads efforts that advance health care equity through innovative collaboration in care, education and research for underserved populations globally. Texas Children's Hospital is affiliated with Baylor College of Medicine. ABOUT TEXAS CHILDREN'S HOSPITAL CENTER FOR VACCINE DEVELOPMENT Texas Children's Hospital Center for Vaccine Development is one of the leading vaccine development centers in the world. Established in Washington DC as the Sabin Vaccine Institute Product Development Partnership (PDP) in the year 2000 and after relocating to the Texas Medical Center in 2011, it rebranded as Texas Children's Center for Vaccine Development. For the past two decades it has acquired an international reputation as a non-profit PDP, advancing vaccines for poverty-related neglected tropical diseases (NTDs) and emerging infectious diseases of pandemic importance. In addition, it builds and strengthens capacity for vaccine development locally and with foreign nations and leads global efforts to guide and influence vaccine policy and advocacy through "vaccine diplomacy" as an international bridge for peace and vaccine development capacity. ABOUT BCM VENTURES Baylor College of Medicine Ventures is the commercial engine of the health sciences university, created to support the translation of academic knowledge and intellectual assets for the benefit of society. We do this by engaging university innovators, entrepreneurs and industry to fully develop ideas along their best commercial path. We foster a culture of commercialization and engage with industry to identify market opportunities for collaborative ventures. ABOUT BIOLOGICAL E. LIMITED Biological E. Limited (BE), a Hyderabad-based Pharmaceuticals & Biologics Company founded in 1953, is the first private sector biological products company in India and the first pharmaceutical company in Southern India. BE develops, manufactures and supplies vaccines and therapeutics. BE supplies its vaccines to over 100 countries and its therapeutic products are sold in India and the USA. BE currently has 8 WHO-prequalified vaccines in its portfolio. In recent years, BE has embarked on new initiatives for organisational expansion such as developing generic injectable products for the regulated markets, exploring synthetic biology and metabolic engineering as a means to manufacture APIs sustainably and developing novel vaccines for the global market.

Read More

MEDICAL DEVICES

Extremity Medical Files Patent Infringement Lawsuit Against Nextremity Solutions, Zimmer Biomet Holdings and Zimmer, Inc.

Extremity Medical, LLC | April 07, 2022

Extremity Medical, LLC, a global medical device company focused on the development of innovative implants and instruments for upper and lower extremities, announcedthat it filed a lawsuit against Nextremity Solutions, Inc.; Zimmer Biomet Holdings, Inc.; and Zimmer, Inc., alleging infringement of an Extremity Medical patent* for its intraosseous fixation platform arising from the marketing of the InCore® Lapidus System by these companies. The complaint was filed in the U.S. District Court for the District of Delaware. Extremity Medical has amassed an intellectual propertyportfolio that includes 49 patents in the U.S. and several foreign countries. The novel and patented technology of Extremity’s intraosseous fixation platform provides surgeons with a zero-profile solution for fusion and fixation of bones within the upper and lower extremities, with the ability to be implanted through minimal incisions. This technology is currently marketed globally by Extremity under the trade names IO FiX, IO FiX Plus, IO FiX 2.0, IO Freedom, CarpalFiX, ApeX and XMCP. “Extremity Medical has invested a tremendous amount of effort and resources in research and development to create innovative technology to improve the lives of patients and meet surgeons’ needs. Our intellectual property is a critical component in making such advancements possible and we are committed to protecting it,” Matthew Lyons, Extremity Medical Chief Executive Officer, Founder and Chairman of the Board About Extremity Medical, LLC Extremity Medical, was founded in 2008, and is a privately-held medical device company based in Parsippany, NJ. The company is known for creating innovative implants and instruments for upper and lower extremity orthopedic procedures, including fusion and motion preservation. The company is focused on developing solutions for challenging cases that promote better outcomes, especially in patients with poor bone quality.

Read More

AI

Faisal Belhoul joins forces with iGan Partners to launch US$250 million iGan Arabia fund to drive MedTech innovation in MENA

iGan Partners | February 08, 2022

iGan Partners,Canada'sleading healthcare technology investors, has joined forces with Faisal Belhoul, aDubai-based investments professional and entrepreneur, to launch aUS$250MiGan Arabia regional fundto drive MedTech innovation across theMiddle EastandNorth Africaregion. iGan Arabia will focus on investing in AI/Cloud-enhanced medical devices and digital health technologies that improve patient outcomes and reduce healthcare cost. The fund targetsUS$250Mthrough limited partnerships with an additionalUS$250Min co-investments. The first four investments have been identified to drive breakthrough MedTech in the region. These areExact Imaging, the world's first micro-ultrasound for unmatched resolution of prostate cancer;Okadoc, the region's most advanced digital patient management solution;eSight Corporation, wearable electronic vision devices for legally blind people challenged by eye diseases; andMolecuLight, the world's first handheld imaging device enabling clinicians to visualize bacteria in real-time for advanced wound care. All these already have regulatory approval and are scaling world-wide. H.E.Jean-Philippe Linteau, Consul General ofCanadainDubaiand the Northern Emirates, commented: "I am pleased to see Canadian and UAE health innovation leaders partner together to create iGan Arabia. The UAE has proven to be an early adopter of innovation. This new partnership will help our healthcare technology companies grow and succeed globally." "We see the GCC as a transformative healthcare region. We have identified and uncovered several innovative opportunities across Digital Health, Connected Medical Devices, Healthcare IT and Artificial Intelligence. These are sectors that iGan brings a lot of expertise and we understand what it takes for companies to scale and succeed. Through this first of its kind Fund, we will invest locally and will showcase the GCC's healthcare innovations to the world." Sam Ifergan, Founder & CEO, iGan Partners Faisal Belhoul, Co-Chairman, iGan Arabia,added: "Through iGan Arabia we aim to invest in start-ups and other healthcare companies, especially in the GCC, and help them evolve as the best-in-class. We will support not only their operations in the region but also help scale up their operations to key markets inNorth America,Europe, and LATAM. iGan Arabia will help establish GCC as a world-class MedTech hub that will create thousands of new jobs and add value to the economy."

Read More

Spotlight

Healthcare executives expect that, within the next three years, their industry will need to focus as much on training machines as they do on training people, according to one finding from a new report by Accenture. The Accenture 2015 Healthcare IT Vision is based on a survey of doctors, consumers and healthcare executives and highlights emerging technology trends that will affect the health industry in the next three to five years. 84% of health executives surveyed agree or strongly agree that healthcare industry will need to focus as much on training machines – such as using algorithms, intelligent software and machine learning – as they do on training people in the next three years.

Resources